[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Elicio Therapeutics Inc (ELTX)

Elicio Therapeutics Inc (ELTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 76,344
  • Shares Outstanding, K 19,086
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,570 K
  • EBIT $ -38 M
  • EBITDA $ -36 M
  • 60-Month Beta 1.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 264.55% (+90.03%)
  • Historical Volatility 429.03%
  • IV Percentile 48%
  • IV Rank 39.11%
  • IV High 576.32% on 11/20/25
  • IV Low 64.29% on 08/15/25
  • Expected Move (DTE 19) 0.13 (3.19%)
  • Put/Call Vol Ratio 0.49
  • Today's Volume 185
  • Volume Avg (30-Day) 1,813
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 26,385
  • Open Int (30-Day) 23,721
  • Expected Range 3.87 to 4.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.53
  • Number of Estimates 2
  • High Estimate $-0.45
  • Low Estimate $-0.60
  • Prior Year $-0.66
  • Growth Rate Est. (year over year) +19.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.66 +50.38%
on 06/16/26
16.00 -75.00%
on 06/10/26
-6.03 (-60.12%)
since 05/26/26
3-Month
2.66 +50.38%
on 06/16/26
16.00 -75.00%
on 06/10/26
-6.82 (-63.03%)
since 03/26/26
52-Week
2.66 +50.38%
on 06/16/26
16.00 -75.00%
on 06/10/26
-3.90 (-49.37%)
since 06/26/25

Most Recent Stories

More News
ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or “the Company”)...

ELTX : 4.00 (+6.67%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX

NEW YORK , June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. ("Elicio" or the "Company") (NASDAQ: ELTX). Such investors are advised...

ELTX : 4.00 (+6.67%)
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer

100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent...

ELTX : 4.00 (+6.67%)
Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)

Elicio Therapeutics reported Q1 2026 results showing a widening net loss and zero revenue days before its lead clinical program failed -- investors who bought ELTX lost 72.5% in a single session.

ELTX : 4.00 (+6.67%)
This Monthly Dividend Powerhouse Is Trading at a Bargain-Bin Valuation

EPR Properties offers income investors a rare combination: a 6.3% monthly dividend yield, a conservative 73% payout ratio, and diversified exposure to experiential real estate well beyond movie theatres,...

CNK : 33.44 (+3.31%)
EPR : 59.70 (+1.12%)
AMC : 2.16 (+14.29%)
ELTX : 4.00 (+6.67%)
RGNT : 3.90 (-6.02%)
FUN : 22.01 (-2.05%)
Stocks Settle Sharply Higher as US-Iran Peace Deal Spurs Optimism

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.65%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.92%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +3.06%. June E-mini S&P...

ALK : 53.86 (+1.07%)
MSTR : 82.31 (-3.54%)
GOOGL : 337.39 (-1.84%)
MPC : 254.06 (+0.20%)
AAPL : 283.78 (+3.14%)
SNDK : 2,090.71 (-10.46%)
HL : 15.54 (+2.57%)
CDE : 16.02 (+0.19%)
SLB : 47.00 (-0.89%)
DASH : 183.09 (+3.49%)
COIN : 149.06 (+4.59%)
OXY : 49.99 (-2.38%)
Stocks Rally as US-Iran Peace Deal Sinks Oil and Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is up +1.67%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.24%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.79%. June E-mini S&P futures (ESM26...

ALK : 53.86 (+1.07%)
MSTR : 82.31 (-3.54%)
GOOGL : 337.39 (-1.84%)
MPC : 254.06 (+0.20%)
AAPL : 283.78 (+3.14%)
TRIP : 13.76 (+7.50%)
SNDK : 2,090.71 (-10.46%)
HL : 15.54 (+2.57%)
CDE : 16.02 (+0.19%)
COIN : 149.06 (+4.59%)
OXY : 49.99 (-2.38%)
TSLA : 379.71 (+1.22%)
Stocks Soar on US-Iran Peace Agreement

The S&P 500 Index ($SPX ) (SPY ) today is up +1.62%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.73%. June E-mini S&P futures (ESM26...

ALK : 53.86 (+1.07%)
MSTR : 82.31 (-3.54%)
GOOGL : 337.39 (-1.84%)
MPC : 254.06 (+0.20%)
AAPL : 283.78 (+3.14%)
TRIP : 13.76 (+7.50%)
SNDK : 2,090.71 (-10.46%)
HL : 15.54 (+2.57%)
CDE : 16.02 (+0.19%)
GLXY : 29.26 (+3.54%)
COIN : 149.06 (+4.59%)
OXY : 49.99 (-2.38%)
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival (“DFS”) in the intent-to-treat population. Randomization balanced most prognostic factors between arms. However,...

ELTX : 4.00 (+6.67%)
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies...

ELTX : 4.00 (+6.67%)

Business Summary

Elicio Therapeutics is a privately-held clinical-stage biotechnology company. It involved in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. Elicio Therapeutics, formerly known as Angion Biomedica Corp, is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 4.66
2nd Resistance Point 4.38
1st Resistance Point 4.19
Last Price 4.00
1st Support Level 3.72
2nd Support Level 3.44
3rd Support Level 3.25

See More

52-Week High 16.00
Fibonacci 61.8% 10.90
Fibonacci 50% 9.33
Fibonacci 38.2% 7.76
Last Price 4.00
52-Week Low 2.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.